Clinical Trials Logo
  1. Home
  2. Mucopolysaccharidosis I
  3. NCT00144781

A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease

Mucopolysaccharidosis I Clinical Trial

Official title:
A Multicenter, Multinational, Randomized, Dose-Optimization Study of the Safety and Pharmacodynamic Response of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I

Clinical Trial Summary

The main purpose of this study is to evaluate differences in the pharmacodynamic response of 4 Aldurazyme® (laronidase) dose regimens in patients with Mucopolysaccharidosis I (MPS I).

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00144781
Study type Interventional
Source Sanofi
Contact
Status Completed
Phase Phase 4
Start date December 2004
Completion date January 2006
View Details
See also
  Status Clinical Trial Phase
Terminated NCT01675674 - Study to Detect Unrecognized Mucopolysaccharidosis in Children Visiting Rheumatology, Hand or Skeletal Dysplasia Clinics N/A
Completed NCT00741338 - Immune Tolerance Study With Aldurazyme® (Laronidase) Phase 1/Phase 2
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Completed NCT04227600 - A Study of JR-171 in Patients With Mucopolysaccharidosis I Phase 1/Phase 2
Active, not recruiting NCT04453085 - An Extension Study of JR-171-101 Study in Patients With MPS I Phase 1/Phase 2
Completed NCT05134571 - China Post-marketing Surveillance (PMS) Study of Aldurazyme® Phase 4
Terminated NCT00418821 - A Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in Female Patients With Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants Phase 4
Completed NCT03071341 - Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I Phase 1/Phase 2
Completed NCT03053089 - Safety and Dose Ranging Study of Human Insulin Receptor MAb-IDUA Fusion Protein in Adults and Children With MPS I Phase 1/Phase 2
Completed NCT00146757 - A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years Old Phase 2
Active, not recruiting NCT04628871 - Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX
Completed NCT02597114 - Extension Study of AGT-181-102 to Evaluate Long Term Safety and Activity of AGT-181 Phase 1
Terminated NCT00748969 - Clinical Trial of Growth Hormone in MPS I, II, and VI Phase 2/Phase 3
Terminated NCT00215527 - Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis (MPS) I Phase 1
Recruiting NCT05619900 - Registry of Patients Diagnosed With Lysosomal Storage Diseases
Completed NCT00146770 - Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients Phase 3
Completed NCT00176917 - Stem Cell Transplantation for Hurler Phase 2
Completed NCT00176891 - Stem Cell Transplant w/Laronidase for Hurler Phase 2
Active, not recruiting NCT03153319 - Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI Phase 1/Phase 2
Completed NCT00852358 - A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I N/A